Skip to main content

Advertisement

SpringerLink
Log in

Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population

  • Review
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

To provide a comprehensive summary of relevant studies and evidence concerning the utilization of different pharmacotherapeutic and revascularization strategies in managing coronary artery disease and acute coronary syndrome specifically in the older adult population.

Recent findings

Approximately 30% to 40% of hospitalized patients with acute coronary syndrome are older adults, among whom the majority of cardiovascular-related deaths occur. When compared to younger patients, these individuals generally experience inferior clinical outcomes. Most clinical trials assessing the efficacy and safety of various therapeutics have primarily enrolled patients under the age of 75, in addition to excluding those with geriatric complexities.

Summary

In this review, we emphasize the need for a personalized and comprehensive approach to pharmacotherapy for coronary heart disease and acute coronary syndrome in older adults, considering concomitant geriatric syndromes and age-related factors to optimize treatment outcomes while minimizing potential risks and complications. In the realm of clinical practice, cardiovascular and geriatric risks are closely intertwined, with both being significant factors in determining treatments aimed at reducing negative outcomes and attaining health conditions most valued by older adults.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. De Luca L, Marini M, Gonzini L, Boccanelli A, Casella G, Chiarella F, De Servi S, Di Chiara A, Di Pasquale G, Olivari Z, Caretta G, Lenatti L, Gulizia MM, Savonitto S. Contemporary trends and age-specific sex differences in management and outcome for patients with ST-segment elevation myocardial infarction. J Am Heart Assoc. 2016;5(12):e004202.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Meid AD, Quinzler R, Freigofas J, Saum KU, Schöttker B, Holleczek B, et al. Medication underuse in aging outpatients with cardiovascular disease: prevalence, determinants, and outcomes in a prospective cohort study. PLoS ONE. 2015;10(8):e0136339.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Martin RC. Disparities in heart failure management in older adults. Curr Geriatr Rep. 2023;12(1):1–6.

    Google Scholar 

  4. Bendz B, Aaberge L. Acute coronary syndromes in older patients: does older age matter? Lancet. 2020;396(10251):585–7.

    Article  PubMed  Google Scholar 

  5. Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of cardiology joint committee on clinical practice guidelines. Circulation. 2023;148(9):e9-119.

    Article  PubMed  Google Scholar 

  6. Damluji AA, Forman DE, Wang TY, Chikwe J, Kunadian V, Rich MW, et al. Management of acute coronary syndrome in the older adult population: a scientific statement from the American Heart Association. Circulation. 2023;147(3):e32-62.

    Article  PubMed  Google Scholar 

  7. Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation. 2011;123(7):798–813.

    Article  PubMed  Google Scholar 

  8. Group BMJP. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.

    Article  Google Scholar 

  9. Collaboration AT. Collaborative overview of randomised trials of antiplatelet therapy prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308(6921):81–106.

    Article  Google Scholar 

  10. Nguyen TNM, Sha S, Chen LJ, Holleczek B, Brenner H, Schöttker B. Strongly increased risk of gastric and duodenal ulcers among new users of low-dose aspirin: results from two large cohorts with new-user design. Aliment Pharmacol Ther. 2022;56(2):251–62.

    Article  CAS  PubMed  Google Scholar 

  11. Li L, Geraghty OC, Mehta Z, Rothwell PM. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 2017;390(10093):490–9.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022;145(3):e18-114.

    PubMed  Google Scholar 

  13. Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381(16):1524–34.

    Article  PubMed  Google Scholar 

  14. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2023;ehad191.

  15. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.

    Article  CAS  PubMed  Google Scholar 

  16. Menichelli M, Neumann FJ, Ndrepepa G, Mayer K, Wöhrle J, Bernlochner I, et al. Age- and weight-adapted dose of prasugrel versus standard dose of ticagrelor in patients with acute coronary syndromes. Ann Intern Med. 2020;173(6):436–44.

    Article  PubMed  Google Scholar 

  17. Savonitto S, Ferri LA, Piatti L, Grosseto D, Piovaccari G, Morici N, et al. Comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization. Circulation. 2018;137(23):2435–45.

    Article  CAS  PubMed  Google Scholar 

  18. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.

    Article  CAS  PubMed  Google Scholar 

  19. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791–800.

    Article  PubMed  Google Scholar 

  20. Szummer K, Montez-Rath ME, Alfredsson J, Erlinge D, Lindahl B, Hofmann R, et al. Comparison between ticagrelor and clopidogrel in elderly patients with an acute coronary syndrome. Circulation. 2020;142(18):1700–8.

    Article  CAS  PubMed  Google Scholar 

  21. Gimbel M, Qaderdan K, Willemsen L, Hermanides R, Bergmeijer T, de Vrey E, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet. 2020;395(10233):1374–81.

    Article  CAS  PubMed  Google Scholar 

  22. Montalto C, Morici N, Munafò AR, Mangieri A, Mandurino-Mirizzi A, D’Ascenzo F, et al. Optimal P2Y12 inhibition in older adults with acute coronary syndromes: a network meta-analysis of randomized controlled trials. Eur Heart J - Cardiovasc Pharmacother. 2022;8(1):20–7.

    Article  PubMed  Google Scholar 

  23. Crimi G, Morici N, Ferrario M, Ferri LA, Piatti L, Grosseto D, et al. Time course of ischemic and bleeding burden in elderly patients with acute coronary syndromes randomized to low-dose prasugrel or clopidogrel. J Am Heart Assoc. 2019;8(2):e010956.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van ’t Hof AWJ, van der Harst P, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381(17):1621–31.

  25. Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2021;42(14):1289–367.

    Article  PubMed  Google Scholar 

  26. Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390(10104):1747–57.

    Article  CAS  PubMed  Google Scholar 

  27. Kralev S, Schneider K, Lang S, Süselbeck T, Borggrefe M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS ONE. 2011;6(9):e24964.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Capodanno D, Huber K, Mehran R, Lip GYH, Faxon DP, Granger CB, et al. Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: JACC state-of-the-art review. J Am Coll Cardiol. 2019;74(1):83–99.

    Article  PubMed  Google Scholar 

  29. Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433–41.

    Article  CAS  PubMed  Google Scholar 

  30. Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381(12):1103–13.

    Article  CAS  PubMed  Google Scholar 

  31. Angiolillo DJ, Bhatt DL, Cannon CP, Eikelboom JW, Gibson CM, Goodman SG, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention. Circulation. 2021;143(6):583–96.

    Article  CAS  PubMed  Google Scholar 

  32. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423–34.

    Article  CAS  PubMed  Google Scholar 

  33. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513–24.

    Article  CAS  PubMed  Google Scholar 

  34. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509–24.

    Article  CAS  PubMed  Google Scholar 

  35. Galli M, Andreotti F, Porto I, Crea F. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients. EP Eur. 2020;22(4):538–46.

  36. Joosten LPT, van Doorn S, van de Ven PM, Köhlen BTG, Nierman MC, Koek HL, et al. Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial. Circulation. 2024;149(4):279–89.

    CAS  PubMed  Google Scholar 

  37. Gundersen T, Abrahamsen AM, Kjekshus J, Rønnevik PK. Timolol-related reduction in mortality and reinfarction in patients ages 65–75 years surviving acute myocardial infarction. Prepared for the Norwegian Multicentre Study Group. Circulation. 1982;66(6):1179–84.

  38. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. The beta-blocker pooling project research group. Eur Heart J. 1988;9(1):8–16.

  39. A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. JAMA. 1982;247(12):1707–14.

  40. Shavadia JS, Holmes DN, Thomas L, Peterson ED, Granger CB, Roe MT, et al. Comparative effectiveness of β-blocker use beyond 3 years after myocardial infarction and long-term outcomes among elderly patients. Circ Cardiovasc Qual Outcomes. 2019;12(7):e005103.

    Article  PubMed  Google Scholar 

  41. Packer M, Fowler MB, Roecker EB, Coats AJS, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure. Circulation. 2002;106(17):2194–9.

    Article  PubMed  Google Scholar 

  42. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385–90.

  43. Gilstrap L, Austin AM, O’Malley AJ, Gladders B, Barnato AE, Tosteson A, et al. Association between beta-blockers and mortality and readmission in older patients with heart failure: an instrumental variable analysis. J Gen Intern Med. 2021;36(8):2361–9.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Zullo AR, Lee Y, Daiello LA, Mor V, John Boscardin W, Dore DD, et al. Beta-blocker use in U.S. Nursing home residents after myocardial infarction: a national study. J Am Geriatr Soc. 2017;65(4):754–62.

  45. Neumann A, Maura G, Weill A, Alla F, Danchin N. Clinical events after discontinuation of β-blockers in patients without heart failure optimally treated after acute myocardial infarction. Circ Cardiovasc Qual Outcomes. 2018;11(4):e004356.

    Article  PubMed  Google Scholar 

  46. Misumida N, Harjai K, Kernis S, Kanei Y. Does oral beta-blocker therapy improve long-term survival in ST-segment elevation myocardial infarction with preserved systolic function? A Meta-Analysis J Cardiovasc Pharmacol Ther. 2016;21(3):280–5.

    Article  CAS  PubMed  Google Scholar 

  47. Zhang H, Yuan X, Zhang H, Chen S, Zhao Y, Hua K, et al. Efficacy of long-term β-blocker therapy for secondary prevention of long-term outcomes after coronary artery bypass grafting surgery. Circulation. 2015;131(25):2194–201.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Puymirat E, Riant E, Aissaoui N, Soria A, Ducrocq G, Coste P, et al. β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ. 2016;20(354):i4801.

    Article  Google Scholar 

  49. Huang BT, Huang FY, Zuo ZL, Liao YB, Heng Y, Wang PJ, et al. Meta-analysis of relation between oral β-blocker therapy and outcomes in patients with acute myocardial infarction who underwent percutaneous coronary intervention. Am J Cardiol. 2015;115(11):1529–38.

    Article  CAS  PubMed  Google Scholar 

  50. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166(17):1842–7.

    Article  PubMed  Google Scholar 

  51. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, et al. β-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13):1340–9.

    Article  CAS  PubMed  Google Scholar 

  52. Dondo TB, Hall M, West RM, Jernberg T, Lindahl B, Bueno H, et al. β-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction. J Am Coll Cardiol. 2017;69(22):2710–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Fukase T, Dohi T, Koike T, Yasuda H, Takeuchi M, Takahashi N, et al. Long-term impact of β-blocker in elderly patients without myocardial infarction after percutaneous coronary intervention. ESC Heart Fail. 2022;9(1):545–54.

    Article  PubMed  Google Scholar 

  54. Steinman MA, Zullo AR, Lee Y, Daiello LA, Boscardin WJ, Dore DD, et al. Association of β-blockers with functional outcomes, death, and rehospitalization in older nursing home residents after acute myocardial infarction. JAMA Intern Med. 2017;177(2):254–62.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW, et al. Acute coronary care in the elderly. Part I Circulation. 2007;115(19):2549–69.

    Article  PubMed  Google Scholar 

  56. Lim SY. Role of statins in coronary artery disease. Chonnam Med J. 2013;49(1):1–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;139(25):e1082–143.

    PubMed  Google Scholar 

  58. Ward NC, Watts GF, Eckel RH. Statin toxicity. Circ Res. 2019;124(2):328–50.

    Article  CAS  PubMed  Google Scholar 

  59. Armitage J, Baigent C, Barnes E, Betteridge DJ, Blackwell L, Blazing M, et al. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407–15.

    Article  Google Scholar 

  60. Collaboration CTT (CTT). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.

  61. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–61.

    Article  CAS  PubMed  Google Scholar 

  62. Bytyçi I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, Sahebkar A, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43(34):3213–23.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Ramkumar S, Raghunath A, Raghunath S. Statin therapy: review of safety and potential side effects. Acta Cardiol Sin. 2016;32(6):631–9.

    PubMed  PubMed Central  Google Scholar 

  64. Matyas C, Trojnar E, Zhao S, Arif M, Mukhopadhyay P, Kovacs A, et al. PCSK9, a promising novel target for age-related cardiovascular dysfunction. JACC Basic Transl Sci. 2023;8(10):1334–53.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Stoll F, Eidam A, Michael L, Bauer JM, Haefeli WE. Drug treatment of hypercholesterolemia in older adults: focus on newer agents. Drugs Aging. 2022;39(4):251–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Sever P, Gouni-Berthold I, Keech A, Giugliano R, Pedersen TR, Im K, et al. LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. Eur J Prev Cardiol. 2021;28(8):805–12.

    Article  PubMed  Google Scholar 

  67. Sinnaeve PR, Schwartz GG, Wojdyla DM, Alings M, Bhatt DL, Bittner VA, et al. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. Eur Heart J. 2020;41(24):2248–58.

    Article  CAS  PubMed  Google Scholar 

  68. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893–906.

    Article  CAS  PubMed  Google Scholar 

  69. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100(23):2312–8.

    Article  CAS  PubMed  Google Scholar 

  70. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374(9704):1840–8.

    Article  CAS  PubMed  Google Scholar 

  71. Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, et al. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2016;18(10):1228–34.

  72. Cusack BJ. Pharmacokinetics in older persons. Am J Geriatr Pharmacother. 2004;2(4):274–302.

    Article  CAS  PubMed  Google Scholar 

  73. Hines LE, Murphy JE. Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011;9(6):364–77.

    Article  CAS  PubMed  Google Scholar 

  74. Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis. 2005;46(6):1080–7.

    Article  CAS  PubMed  Google Scholar 

  75. Ho JK, Moriarty F, Manly JJ, Larson EB, Evans DA, Rajan KB, et al. Blood-brain barrier crossing renin-angiotensin drugs and cognition in the elderly: a meta-analysis. Hypertension. 2021;78(3):629–43.

    Article  CAS  PubMed  Google Scholar 

  76. Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, et al. Angiotensin receptor-neprilysin inhibition in acute myocardial infarction. N Engl J Med. 2021;385(20):1845–55.

    Article  CAS  PubMed  Google Scholar 

  77. Jering KS, Claggett B, Pfeffer MA, Granger C, Køber L, Lewis EF, et al. Prospective ARNI vs. ACE inhibitor trial to determine superiority in reducing heart failure events after myocardial infarction (PARADISE-MI): design and baseline characteristics. Eur J Heart Fail. 2021;23(6):1040–8.

  78. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non–st-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update) [Internet]. [cited 2024 Feb 10]. Available from: https://www.ahajournals.org/doi/epub/10.1161/CIR.0b013e318256f1e0

  79. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21.

    Article  CAS  PubMed  Google Scholar 

  80. Wang TY, Vora AN, Peng SA, Fonarow GC, Das S, de Lemos JA, et al. Effectiveness and safety of aldosterone antagonist therapy use among older patients with reduced ejection fraction after acute myocardial infarction. J Am Heart Assoc. 5(1):e002612.

  81. Kalra S. Sodium glucose Co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. Diabetes Ther. 2014;5(2):355–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Baigent C, Emberson J, Haynes R, Herrington WG, Judge P, Landray MJ, et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788–801.

    Article  Google Scholar 

  83. Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Bělohlávek J, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323(14):1353–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.

    Article  CAS  PubMed  Google Scholar 

  85. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24.

    Article  CAS  PubMed  Google Scholar 

  86. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819–29.

    Article  PubMed  Google Scholar 

  87. Wiggins BS, Saseen JJ, Page RL, Reed BN, Sneed K, Kostis JB, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134(21):e468–95.

    Article  PubMed  Google Scholar 

  88. Van Horn L, Carson JAS, Appel LJ, Burke LE, Economos C, Karmally W, et al. Recommended dietary pattern to achieve adherence to the American Heart Association/American College of Cardiology (AHA/ACC) guidelines: a scientific statement from the American Heart Association. Circulation. 2016;134(22):e505–29.

    PubMed  Google Scholar 

  89. Engler C, Leo M, Pfeifer B, Juchum M, Chen-Koenig D, Poelzl K, et al. Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012–2018. BMJ Open Diabetes Res Care. 2020;8(1):e001279.

    Article  PubMed  PubMed Central  Google Scholar 

  90. McGill JB, Subramanian S. Safety of sodium-glucose Co-transporter 2 inhibitors. Am J Med. 2019;132(10, Supplement):S49-S57.e5.

  91. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

    Article  CAS  PubMed  Google Scholar 

  92. Cahn A, Mosenzon O, Wiviott SD, Rozenberg A, Yanuv I, Goodrich EL, et al. Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE–TIMI 58 study. Diabetes Care. 2020;43(2):468–75.

    Article  CAS  PubMed  Google Scholar 

  93. Pratley RE, Cannon CP, Cherney DZI, Cosentino F, McGuire DK, Essex MN, et al. Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. Lancet Healthy Longev. 2023;4(4):e143–54.

    Article  PubMed  Google Scholar 

  94. Butt JH, Jhund PS, Belohlávek J, de Boer RA, Chiang CE, Desai AS, et al. Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial. Circulation. 2022;146(16):1210–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Clemens KK, Liu K, Shariff S, Schernthaner G, Tangri N, Garg AX. Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004–2013. Diabetes Obes Metab. 2016;18(6):607–14.

    Article  CAS  PubMed  Google Scholar 

  96. Baquero GA, Rich MW. Perioperative care in older adults. J Geriatr Cardiol JGC. 2015;12(5):465–9.

    PubMed  Google Scholar 

  97. Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, et al. Stopping vs. continuing aspirin before coronary artery surgery. N Engl J Med. 2016;374(8):728–37.

  98. Gerstein NS, Albrechtsen CL, Mercado N, Cigarroa JE, Schulman PM. A comprehensive update on aspirin management during noncardiac surgery. Anesth Analg. 2020;131(4):1111–23.

    Article  PubMed  Google Scholar 

  99. Banerjee S, Angiolillo DJ, Boden WE, Murphy JG, Khalili H, Hasan AA, et al. Use of antiplatelet therapy/DAPT for post-PCI patients undergoing noncardiac surgery. J Am Coll Cardiol. 2017;69(14):1861–70.

    Article  PubMed  Google Scholar 

  100. Moster M, Bolliger D. Perioperative guidelines on antiplatelet and anticoagulant agents: 2022 update. Curr Anesthesiol Rep. 2022;12(2):286–96.

    Article  Google Scholar 

  101. Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;64(22):e77-137.

    Article  PubMed  Google Scholar 

  102. Durazzo AES, Machado FS, Ikeoka DT, De Bernoche C, Monachini MC, Puech-Leão P, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg. 2004;39(5):967–75.

    Article  PubMed  Google Scholar 

  103. Berwanger O, de Barros E Silva PGM, Barbosa RR, Precoma DB, Figueiredo EL, Hajjar LA, et al. Atorvastatin for high-risk statin-naïve patients undergoing noncardiac surgery: the Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial. Am Heart J. 2017;184:88–96.

  104. Turan A, You J, Shiba A, Kurz A, Saager L, Sessler DI. Angiotensin converting enzyme inhibitors are not associated with respiratory complications or mortality after noncardiac surgery. Anesth Analg. 2012;114(3):552.

    Article  CAS  PubMed  Google Scholar 

  105. Rajani R, Lindblom M, Dixon G, Khawaja MZ, Hildick-Smith D, Holmberg S, et al. Evolving trends in percutaneous coronary intervention. Br J Cardiol. 2011;18(2):73–6.

    Google Scholar 

  106. Sabatine MS, Bergmark BA, Murphy SA, O’Gara PT, Smith PK, Serruys PW, et al. Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. Lancet. 2021;398(10318):2247–57.

    Article  CAS  PubMed  Google Scholar 

  107. Stouffer GA, Mott L, Brizolara A, Subbarao V. Left main coronary artery disease in adults younger than 50 years: A comparison with older patients. Catheter Cardiovasc Interv. 2000;51(1):11–7.

    Article  CAS  PubMed  Google Scholar 

  108. null null, O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. Circulation. 2013;127(4):e362–425.

  109. Bueno H, Betriu A, Heras M, Alonso JJ, Cequier A, García EJ, et al. Primary angioplasty vs. fibrinolysis in very old patients with acute myocardial infarction: TRIANA (TRatamiento del Infarto Agudo de miocardio eN Ancianos) randomized trial and pooled analysis with previous studies. Eur Heart J. 2011;32(1):51–60.

  110. Biscaglia S, Guiducci V, Escaned J, Moreno R, Lanzilotti V, Santarelli A, et al. Complete or culprit-only PCI in older patients with myocardial infarction. N Engl J Med. 2023;389(10):889–98.

    Article  PubMed  Google Scholar 

  111. Gnanenthiran SR, Kritharides L, D’Souza M, Lowe HC, Brieger DB. Revascularisation compared with initial medical therapy for non-ST-elevation acute coronary syndromes in the elderly: a meta-analysis. Heart. 2017;103(24):1962–9.

    PubMed  Google Scholar 

  112. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes | circulation [internet]. [cited 2023 Sep 12]. Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000134

  113. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A validated prediction model for all forms of acute coronary syndromeestimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291(22):2727–33.

    Article  CAS  PubMed  Google Scholar 

  114. Scruth EA, Cheng E, Worrall-Carter L. Risk score comparison of outcomes in patients presenting with ST-elevation myocardial infarction treated with percutaneous coronary intervention. Eur J Cardiovasc Nurs. 2013;12(4):330–6.

    Article  PubMed  Google Scholar 

  115. Fox KAA, FitzGerald G, Puymirat E, Huang W, Carruthers K, Simon T, et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open. 2014;4(2):e004425.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019;140(3):240–61.

    Article  PubMed  PubMed Central  Google Scholar 

  117. Damluji AA, Forman DE, van Diepen S, Alexander KP, Page RL, Hummel SL, et al. Older adults in the cardiac intensive care unit: factoring geriatric syndromes in the management, prognosis, and process of care: a scientific statement from the American Heart Association. Circulation. 2020;141(2):e6-32.

    Article  PubMed  Google Scholar 

  118. Mehta SR, Cannon CP, Fox KAA, Wallentin L, Boden WE, Spacek R, et al. Routine vs selective invasive strategies in patients with acute coronary syndromesa collaborative meta-analysis of randomized trials. JAMA. 2005;293(23):2908–17.

    Article  CAS  PubMed  Google Scholar 

  119. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354(9180):708–15.

  120. Rosa RD, Morici N, Luca GD, Luca LD, Ferri LA, Piatti L, et al. Association of sex with outcome in elderly patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Med. 2021;134(9):1135-1141.e1.

    Article  PubMed  Google Scholar 

  121. Sanchis J, Núñez E, Barrabés JA, Marín F, Consuegra-Sánchez L, Ventura S, et al. Randomized comparison between the invasive and conservative strategies in comorbid elderly patients with non-ST elevation myocardial infarction. Eur J Intern Med. 2016;1(35):89–94.

    Article  Google Scholar 

  122. Hirlekar G, Libungan B, Karlsson T, Bäck M, Herlitz J, Albertsson P. Percutaneous coronary intervention in the very elderly with NSTE-ACS: the randomized 80+ study. Scand Cardiovasc J. 2020;54(5):315–21.

    Article  PubMed  Google Scholar 

  123. Belder A de, Myat A, Blaxill J, Haworth P, O’Kane P, Hatrick R, et al. EuroIntervention. [cited 2023 Sep 12]. Revascularisation or medical therapy in elderly patients with acute anginal syndromes: the RINCAL randomised trial. Available from: https://eurointervention.pcronline.com/article/revascularisation-or-medical-therapy-in-elderly-patients-with-acute-anginal-syndromes-rincal-a-randomised-trial.

  124. Tegn N, Abdelnoor M, Aaberge L, Endresen K, Smith P, Aakhus S, et al. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. Lancet. 2016;387(10023):1057–65.

    Article  PubMed  Google Scholar 

  125. Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carrié D, et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet. 2018;391(10115):41–50.

    Article  CAS  PubMed  Google Scholar 

  126. Valgimigli M, Gagnor A, Calabró P, Frigoli E, Leonardi S, Zaro T, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015;385(9986):2465–76.

    Article  PubMed  Google Scholar 

  127. Tehrani BN, Damluji AA, Sherwood MW, Rosner C, Truesdell AG, Epps KC, et al. Transradial access in acute myocardial infarction complicated by cardiogenic shock: Stratified analysis by shock severity. Catheter Cardiovasc Interv. 2021;97(7):1354–66.

    Article  PubMed  Google Scholar 

  128. Dobaria V, Hadaya J, Sanaiha Y, Aguayo E, Sareh S, Benharash P. The pragmatic impact of frailty on outcomes of coronary artery bypass grafting. Ann Thorac Surg. 2021;112(1):108–15.

    Article  PubMed  Google Scholar 

  129. Tran DTT, Tu JV, Dupuis J, Bader Eddeen A, Sun LY. Association of frailty and long-term survival in patients undergoing coronary artery bypass grafting. J Am Heart Assoc. 2018;7(15):e009882.

    Article  PubMed  PubMed Central  Google Scholar 

  130. Kochar A, Deo SV, Charest B, Peterman-Rocha F, Elgudin Y, Chu D, et al. Preoperative frailty and adverse outcomes following coronary artery bypass grafting surgery in US veterans. J Am Geriatr Soc. 2023;71(9):2736–47.

    Article  PubMed  Google Scholar 

  131. Alkhouli M, Alqahtani F, Kalra A, Gafoor S, Alhajji M, Alreshidan M, et al. Trends in characteristics and outcomes of hospital inpatients undergoing coronary revascularization in the United States, 2003–2016. JAMA Netw Open. 2020;3(2):e1921326.

    Article  PubMed  Google Scholar 

  132. ElBardissi AW, Aranki SF, Sheng S, O’Brien SM, Greenberg CC, Gammie JS. Trends in isolated coronary artery bypass grafting: an analysis of the society of thoracic surgeons adult cardiac surgery database. J Thorac Cardiovasc Surg. 2012;143(2):273–81.

    Article  PubMed  Google Scholar 

  133. Filsoufi F, Rahmanian PB, Castillo JG, Chikwe J, Silvay G, Adams DH. Results and predictors of early and late outcomes of coronary artery bypass graft surgery in octogenarians. J Cardiothorac Vasc Anesth. 200AD;21(6):784–92.

    Article  PubMed  Google Scholar 

  134. Chang M, Lee CW, Ahn JM, Cavalcante R, Sotomi Y, Onuma Y, et al. Outcomes of coronary artery bypass graft surgery versus drug-eluting stents in older adults. J Am Geriatr Soc. 2017;65(3):625–30.

    Article  PubMed  Google Scholar 

  135. Khan MR, Kayani WT, Ahmad W, Manan M, Hira RS, Hamzeh I, et al. Effect of increasing age on percutaneous coronary intervention vs coronary artery bypass grafting in older adults with unprotected left main coronary artery disease: A meta-analysis and meta-regression. Clin Cardiol. 2019;42(11):1071–8.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Palmerini T, Serruys P, Kappetein AP, Genereux P, Riva DD, Reggiani LB, et al. Clinical outcomes with percutaneous coronary revascularization vs coronary artery bypass grafting surgery in patients with unprotected left main coronary artery disease: a meta-analysis of 6 randomized trials and 4,686 patients. Am Heart J. 2017;1(190):54–63.

    Article  Google Scholar 

  137. Whitlock EL, Diaz-Ramirez LG, Smith AK, Boscardin WJ, Covinsky KE, Avidan MS, et al. Association of coronary artery bypass grafting vs percutaneous coronary intervention with memory decline in older adults undergoing coronary revascularization. JAMA. 2021;325(19):1955–64.

    Article  PubMed  PubMed Central  Google Scholar 

  138. O’Brien SM, Feng L, He X, Xian Y, Jacobs JP, Badhwar V, et al. The society of thoracic surgeons 2018 adult cardiac surgery risk models: part 2—statistical methods and results. Ann Thorac Surg. 2018May 1;105(5):1419–28.

    Article  PubMed  Google Scholar 

  139. Diegeler A, Börgermann J, Kappert U, Breuer M, Böning A, Ursulescu A, et al. Off-pump versus on-pump coronary-artery bypass grafting in elderly patients. N Engl J Med. 2013;368(13):1189–98.

    Article  CAS  PubMed  Google Scholar 

  140. Olenski AR, Zimerman A, Coussens S, Jena AB. Behavioral heuristics in coronary-artery bypass graft surgery. N Engl J Med. 2020;382(8):778–9.

    Article  PubMed  PubMed Central  Google Scholar 

  141. Böning A, Diegeler A, Hilker M, Zacher M, Reents W, Faerber G, et al. Preoperative atrial fibrillation and outcome in patients undergoing on-pump or off-pump coronary bypass surgery: lessons learned from the GOPCABE trial. Interact Cardiovasc Thorac Surg. 2015;20(1):74–8.

    Article  PubMed  Google Scholar 

  142. Llorens-Ortega R, Bertran-Noguer C, Juvinyà-Canals D, Garre-Olmo J, Bosch-Farré C. Influence of social determinants of health in the evolution of the quality of life of older adults in Europe: a comparative analysis between men and women. Humanit Soc Sci Commun. 2024;11(1):1–13.

    Article  Google Scholar 

  143. Iung B. Interface between valve disease and ischaemic heart disease. Heart Br Card Soc. 2000;84(3):347–52.

    Article  CAS  Google Scholar 

  144. Kvidal P, Bergström R, Hörte LG, Ståhle E. Observed and relative survival after aortic valve replacement. J Am Coll Cardiol. 2000;35(3):747–56.

    Article  CAS  PubMed  Google Scholar 

  145. Matta A, Moussallem N. Coronary artery disease is associated with valvular heart disease, but could it Be a predictive factor? Indian Heart J. 2019;71(3):284–7.

    Article  PubMed  PubMed Central  Google Scholar 

  146. Grubb KJ, Nazif T, Williams MR, George I. Concurrent coronary artery and valvular heart disease – hybrid treatment strategies in 2013. Interv Cardiol Rev. 2013;8(2):127–30.

    Article  Google Scholar 

  147. Brinster DR, Byrne M, Rogers CD, Baim DS, Simon DI, Couper GS, et al. Effectiveness of same day percutaneous coronary intervention followed by minimally invasive aortic valve replacement for aortic stenosis and moderate coronary disease (“hybrid approach”). Am J Cardiol. 2006;98(11):1501–3.

    Article  PubMed  Google Scholar 

  148. Otto CM, Nishimura RA, Bonow RO, Carabello BA, III JPE, Gentile F, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation [internet]. 2021 Feb 2 [cited 2024 Feb 11]; Available from: https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000000923

  149. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med. 2002;137(7):563–70.

    Article  PubMed  Google Scholar 

  150. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med. 2002;137(7):555–62.

    Article  PubMed  Google Scholar 

  151. Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis. 2005;45(3):473–84.

    Article  CAS  PubMed  Google Scholar 

  152. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.

  153. Steinhubl SR, Berger PB, Mann JT III, Fry ETA, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary interventiona randomized controlled trial. JAMA. 2002;288(19):2411–20.

    Article  CAS  PubMed  Google Scholar 

  154. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation | NEJM [internet]. [cited 2024 Feb 11]. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa050522

  155. Washam JB, Herzog CA, Beitelshees AL, Cohen MG, Henry TD, Kapur NK, et al. Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome. Circulation. 2015;131(12):1123–49.

    Article  PubMed  Google Scholar 

  156. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet Lond Engl. 2009;373(9678):1849–60.

  157. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529–39.

  158. Zoungas S, Curtis A, Spark S, Wolfe R, McNeil JJ, Beilin L, et al. Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial). BMJ Open. 2023;13(4):e069915.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

No funding.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Errol Moras & Kruti Gandhi

  2. Section of Cardiology, Baylor College of Medicine, Houston, TX, USA

    Syed Zaid & Yochai Birnbaum

  3. Cardiac Catheterization Laboratory, Mount Sinai Morningside Hospital, New York, NY, USA

    Nitin Barman

  4. The Aga Khan University, Karachi, Pakistan

    Salim S. Virani

  5. Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA

    Jacqueline Tamis-Holland

  6. Division of Cardiology, University of Texas Medical Branch, Houston, TX, USA

    Hani Jneid

  7. Cardiology Division, NYU Langone Health and NYU School of Medicine, New York, NY, USA

    Chayakrit Krittanawong

Authors
  1. Errol Moras
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Syed Zaid
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kruti Gandhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nitin Barman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yochai Birnbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Salim S. Virani
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jacqueline Tamis-Holland
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hani Jneid
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chayakrit Krittanawong
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

EM, SZ, KG, NB wrote the main manuscript text and EM prepared figures. YB, SSV, JT, HJ and CK reviewed and edited the manuscript. All authors reviewed the manuscript

Corresponding author

Correspondence to Chayakrit Krittanawong.

Ethics declarations

Competing Interests

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moras, E., Zaid, S., Gandhi, K. et al. Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population. Curr Atheroscler Rep (2024). https://doi.org/10.1007/s11883-024-01203-9

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11883-024-01203-9

Keywords

Search

Navigation